Aspetar Orthopaedic and Sports Medicine Hospital, Doha, Qatar.
Cartilage. 2023 Dec;14(4):433-444. doi: 10.1177/19476035231166127. Epub 2023 Jun 22.
OBJECTIVE: To directly compare clinical and MRI outcomes of multiple intra-articular injections of adipose-derived stromal cells (ASCs) or platelet-rich plasma (PRP) in patients with knee osteoarthritis (OA). DESIGN: We retrospectively compared 24-month outcomes in (1) 27 patients receiving 3-monthly intra-articular injections with a total of 43.8 million ASCs and (2) 23 patients receiving 3-monthly injections of 3-ml preparation of PRP. All patients had Kellgren-Lawrence grade 1, 2, or 3 knee OA with failed conservative medical therapy. The Numeric Pain Rating Scale (NPRS) scores; Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline, 6, 12, and 24 months after the first injection; and the MRI Osteoarthritis Knee Score (MOAKS) at 12 and 24 months were considered as outcomes. RESULTS: No major complications occurred in any patient. Both groups significantly improved in pain NPRS score and KOOS at 6 months. At 12- and 24-month evaluations, the ASC group significantly decreased scores to a greater degree ( < 0.001) than the PRP group. MOAKS scores indicated a decrease in disease progression in the ASC group. CONCLUSION: Both ASCs and PRP were safe and resulted in clinical improvement in patients with knee OA at 6 months; however, at 12 and 24 months, ASCs outperformed leukocyte-poor PRP in clinical and radiological outcomes.
目的:直接比较膝关节骨关节炎(OA)患者多次关节内注射脂肪来源基质细胞(ASCs)或富含血小板的血浆(PRP)的临床和 MRI 结果。
设计:我们回顾性比较了 27 名患者在 3 个月内接受共 4380 万 ASC 单次关节内注射和 23 名患者在 3 个月内接受 3 毫升 PRP 制备物注射的 24 个月的结果。所有患者均有 Kellgren-Lawrence 分级 1、2 或 3 级膝 OA,且经保守药物治疗失败。数值疼痛评分量表(NPRS)评分、首次注射后 6、12 和 24 个月的膝关节损伤和骨关节炎结果评分(KOOS)以及 12 和 24 个月的 MRI 骨关节炎膝关节评分(MOAKS)被认为是结果。
结果:任何患者均未发生重大并发症。两组患者的疼痛 NPRS 评分和 KOOS 在 6 个月时均显著改善。在 12 个月和 24 个月评估时,ASC 组的评分下降程度明显大于 PRP 组(<0.001)。MOAKS 评分表明 ASC 组疾病进展程度降低。
结论:ASCs 和 PRP 均安全,可在 6 个月时改善膝 OA 患者的临床症状;然而,在 12 个月和 24 个月时,白细胞减少的 PRP 与 ASC 相比,在临床和影像学结果方面表现不佳。
Orthop J Sports Med. 2022-9-16
Int J Mol Sci. 2021-9-30
Clin Med Insights Arthritis Musculoskelet Disord. 2020-7-3